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Background and purpose   Allografts are often used during revi-
sion hip replacement surgery for stabilization of the implant. 
Resorption of the allograft may exceed new bone formation, and 
instability of the prosthesis can develop. We investigated whether 
strontium could regulate the imbalance of fast resorption of 
allograft and slower formation of new bone, because it is both an 
anabolic and an anticatabolic agent.
Method   Strontium was added to the implant interface envi-
ronment by doping a hydroxyapatite bone graft extender. 10 dogs 
each received 2 experimental titanium implants. The implants 
were inserted within a 2.7-mm concentric gap in cancellous bone. 
The gap was filled with 50% (v/v) allograft mixed with 50% bone 
graft extender. The extender either had 5% strontium doping 
(SrHA) or was undoped (HA). After 4 weeks, osseointegration 
and mechanical fixation were evaluated by histomorphometry 
and by push-out test.
Results   SrHA bone graft extender induced a 1.2-fold increase 
in volume of new bone, a 1.2-fold increase in allograft remaining 
in the gap, and a 1.4-fold increase in surface area of the bone graft 
extender material in contact with new bone compared to HA bone 
graft extender. All these increases were statistically significant.   
SrHA bone graft extender did not significantly improve ongrowth 
of bone onto the implants or improve any of the mechanical push-
out parameters compared to HA bone graft extender. 
Interpretation   Doping of the HA bone graft extender with 5% 
strontium increased gap healing, preserved more of the allograft 
in the gap, and increased the ongrowth of bone onto the bone 
graft extender material, but did not improve mechanical fixation.

Due to longer life expectancy and younger ages at index opera-
tion, up to one fifth of hip replacement surgeries are now revi-
sions. The main indication for revision is painful aseptic loos-
ening of the prosthesis (Pedersen et al. 2005), during which 
periprosthetic bone loss frequently occurs. Thus, in revision 
surgery allografts are often used to stabilize the prosthesis. 
However, imbalanced rapid allograft resorption and slower 
formation of new bone (for mechanically securing the implant 
by osseointegration) have been found experimentally and may 
result in instability of allografted implants (Burchardt 1983, 
Jakobsen et al. 2010). This imbalance may partly explain the 
higher re-revision rate for allografted uncemented acetabular 
components compared to non-allografted components (Lie et 
al. 2004). Reduction of this imbalance may improve the out-
come of allografted revision hip prostheses. Strontium is a 
candidate for this process, because it has both anabolic and 
anticatabolic effects in bone (Marie et al. 1993). Furthermore, 
synthetic strontium hydroxyapatite is highly biocompatible 
and is believed to promote bone ingrowth (Xue et al. 2007, 
Tian et al. 2009).
We compared strontium-doped hydroxyapatite (SrHA) with 
hydroxyapatite (HA) as a bone graft extender (BGE). Our pur-
pose was 2-fold. The first was to add a local anabolic and anti-
catabolic effect, which strontium is thought to provide. The 
second purpose was to maintain graft material for longer time; 
thus, the allograft was mixed with BGE, because the BGE is 
slowly or even not at all resorbed (Hannink et al. 2007, Fellah 
et al. 2008). The main hypothesis was that strontium doping 
of the BGE would improve fixation of grafted implants, both 
histologically and mechanically.
Methods and materials
We tested our hypothesis in a paired study in 10 dogs. The 2 
treatment arms consisted of: (1) allograft mixed with stron-
tium-doped hydroxyapatite (SrHA) BGE, and (2) allograft 
mixed with hydroxyapatite (HA) BGE. The graft mixtures 
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seal part of the proximal humerus (Figure 1). 
Implants
The experimental implants were a 10-mm high cylinder con-
sisting of a core and a coating made of ASTM-136 (Ti6Al4V) 
titanium (Ti) alloy. The diameter of the cores was 4.4 mm 
and the final mean diameter after coating was 5.7 (SD 0.2) 
mm. The coating was a commercially available bead-sintered 
porous Ti coating, donated by DePuy Inc. (Figure 1). Ti end-
screws, 11.0 mm in diameter, were attached to the top and 
bottom of the implant and ensured a concentric 2.7-mm gap 
around the implant. The overall length of the implant with 
mounted screws was 12.0 mm.
Bone graft extender
A precipitate of calcium-strontium hydroxyapatite was used 
as an experimental bone graft extender. It was prepared as fol-
lows.
Solid crystals of calcium HA with 5% calcium substituted 
by strontium were prepared by the method of Kumta et al. 
(2005) with minor modifications to the synthesis. The synthe-
sis was performed according to the reaction equation:
9.507Ca2+(aq) + 0.493Sr2+(aq) + 6(PO4)3-(aq) + 2OH-(aq) 
→ Ca9.514Sr0.493(PO4)6(OH)2 (s)
In the first 2-L beaker, 190 g of trisodium phosphate 
(Na3PO4) (CAS 7601-54-9; Sigma-Aldrich cat. no. 342483, 
batch 03621 HE) was partially dissolved in 1 L of Millipore 
water. After addition of 15.5 g of NaOH (CAS 1310-73-2; 
Sigma-Aldrich cat. no. 22146-5, lot 540948-277), the sus-
pension was gently heated to 50°C until all the material was 
dissolved. In the second 2-L beaker, 268 g of calcium chlo-
ride dihydrate (CAS 10035-04-8; Fluka lot 1160484, filling 
code 50305149) and 30.4 g of strontium chloride hexahydrate 
(CAS 10025-70-4; Fluka lot 1094650, filling code 53404170) 
were dissolved in 1 L Millipore water. The solution in the first 
beaker containing trisodium phosphate and NaOH was trans-
ferred to a 5-L beaker with a stirrer, and the contents of the 
second beaker were slowly added with vigorous stirring for 
6 h. A small-grained white precipitate was then formed. The 
solution was centrifuged for 5 min at 2,000 rpm and the pre-
cipitate flushed 5 times with Millipore water. The powder thus 
obtained was transferred to an aluminium beaker and heated 
to 1,000°C by increasing the temperature by 200°C per hour, 
and this temperature was maintained for 10 h. The oven was 
allowed to cool to room temperature over 12 h. The powder 
was kept sterile while it was ground in a mortar, weighed, 
and separated into batches of granules of 0.6–2 mm in diam-
eter, which were packed individually in portions of 1.0 mL 
in double sterile containers ready for surgery. The yield was 
92.6%, and by using X-ray powder diffraction (Diffractom-
eter Huber G670; HUBER Diffraktionstechnik GmbH & Co. 
KG, Rimsting, Germany; 1.54060 wavelength, 1 h exposure 
time), the hydroxyapatite structure was confirmed (Figure 2). 
By inductively-coupled plasma mass spectrometry, the stron-
tium content was determined to be 4.93%. The procedure was 
repeated for production of HA powder without adding SrCl 
(Table 1).
The bone graft extenders were produced and donated by 
Osteologix ApS, Copenhagen, Denmark.
Allograft
2 weeks before surgery, bones for bone graft were harvested 
under sterile conditions from 2 dogs not included in the study, 
and stored at –80°C. The proximal humerus and the distal 
femurs were used. All soft tissue and cartilage was removed 
and the bones were morselized with a Biomet bone mill, cre-
Figure 1. Position of the cylindrical implant with mounted end-screws 
in the proximal humerus with a surrounding 2.7-mm gap filled with 
allograft mixed with HA or SrHA.
Figure 2. Strontium content of 4.93% for SrHA was determined by 
X-ray power diffraction (XRPD). 
Table 1. The chemical formulae of SrHA and HA
SrHA Ca9.507Sr0.493(PO4)6(OH)2
HA Ca10(PO4)6(OH)2616  Acta Orthopaedica 2011; 82 (5): 614–621
ating bone chips of 1–2 mm in size. The chips from differ-
ent bones in different dogs were mixed together, portioned 
in sterile double containers, and refrozen at –80°C. The bone 
graft was thawed immediately before surgery. At surgery, the 
impacted allograft was divided into two 1-mL portions in a 
standardized container.
Animals
We used 10 female, skeletally mature American foxhounds 
(mean age 12.5 (SD 1.2) months and mean weight 25.1 (SD 1) 
kg). The number of dogs required in this study was estimated 
from the formula for paired studies with normally distributed 
data. Based on previous studies, we expected an average coef-
ficient of variation (CV)% ((SD / mean) × 100%) of 30% for 3 
main variables: ultimate shear strength, gap healing by bone, 
and implant-bone ongrowth (Baas et al. 2008). We wanted to 
be able to detect an improvement in implant fixation between 
the groups of at least 30%. Based on these assumptions, 10 
animals were included.
Positioning of the implants for each treatment arm was 
alternated systematically with a random start regarding the 
right and left humerus. The NIH guidelines for care and use 
of laboratory animals were observed, and the study was per-
formed in our AAALAC-approved animal care facility. Min-
neapolis Medical Research Foundation, and the Animal Care 
and Use Committee approved the protocol of the study.
 
Surgical procedure
Surgery was conducted under aseptic conditions with general 
anesthesia (initiated with intravenous thiopental (5%) and 
maintained with isoflurane gas (1.5%)). A 7-cm skin incision 
was made with cautery on the lateral proximal humerus, and 
the deltoid muscle was bluntly dissected to expose the proxi-
mal part of the humerus. A 2.5-mm guide wire was inserted 
anterolaterally at the level of the greater tubercle and oriented 
perpendicular to the surface. Over the guide wire, a cannu-
lated drill (11.0-mm diameter) was used to drill a 12-mm 
deep cylindrical cavity at a maximum speed of 2 rotations per 
second. The edge of the hole was trimmed with a scalpel to 
remove periosteum, and the cavity was irrigated with 10 mL 
saline for removal of bone chips.
An implant with a mounted bottom screw was inserted into 
the cavity. A graft mixture of standardized volume (1 mL 
allograft and 1mL SrHA or HA) was tightly packed around 
the implant in the 2.7-mm gap and the top screw was mounted. 
When hemostasis was ensured, the soft tissue was closed in 
layers. The procedure was repeated for the contralateral 
humerus using the other bone graft mixture.
The dogs were given ceftriaxone (1 g i.v) and buprenor-
phine hydrochloride (0.0075 mg/kg/day i.m) immediately 
before and for 3 days after surgery. 
The observation period of 4 weeks was uneventful. All the 
animals were fully mobilized within 2–3 days, and there were 
no clinical signs of infection at any point.
After 4 weeks, the dogs were sedated and killed with an 
overdose of hypersaturated barbiturate.
Preparation of specimens
The proximal humeri were retrieved en bloc and, immediately 
after explantation, were frozen and stored at –20°C. Using 
a water-cooled-wheel diamond saw, the bone/implant speci-
men blocks were cut into 2 transverse blocks: a 3-mm thick 
block of the outermost part of the specimen block was cut 
and returned to the freezer for mechanical testing and a 6-mm 
thick block of the innermost part of the specimen block was 
cut for histomorphometrical analysis (Figure 3).
Histomorphometry
Our main interest in this study was the status of the tissues 
present in the gap after 4 weeks. Unbiased volume density and 
surface area density of the synthetic bone graft granules was 
estimated. Systematic uniform random sampling technique 
combined with isotropic uniform random stereological design 
used for obtaining unbiased estimates of: 1, volume of tissue 
and material in the gap, and 2, surface area of the BGE gran-
ules in contact with tissue. The surface of the granules was 
highly irregular and was therefore considered isotropic. A ste-
reological model of a perfect cylinder was used to estimate 
surface area density of the cylindrical implants (Vestermark 
2011).
The 6-mm block specimens were fixed and dehydrated 
in graded ethanol (70–100%) prior to cold embedding in 
poly(methylmethacrylate) (Erben 1997). Then they were 
sectioned, with orientation perpendicular to the axis of the 
implant. This produced 10–15, 125-µm thick sections per 
implant with an average distance of 420 µm between sections. 
Every 2 to 3 sections, 5 sections in total per implant, were 
sampled for the analysis, and their surfaces were stained with 
toluidine blue at pH 7. Tissue classification was based on mor-
phology: new bone was a disorganized, dense substance with 
embedded cells colored dark purple; allograft was a dense 
substance with empty cell lacunae and clear cement lines col-
ored pale purple. Bone marrow was a cell-rich conglomerate 
with intervening empty areas from dissolved fat and few scat-
tered thread-like structures. Fibrous tissue was dense, with 
well-organized bundles of fibers with sparsely intervening 
Figure 3. Preparation of the specimens and the transverse cutting 
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small cells. BGE was identified as coarsely profiled shadows.
Osseointegration (gap healing and ongrowth) was estimated 
in a predefined region of interest (ROI) manually drawn 
from an applied grid of 2 centralized circles: an inner circle 
2.9 mm in diameter to centralize the ROI with regard to the 
implant, and an outer circle 10.5 mm in diameter to outline 
the ROI at a distance of 2.45 mm out into the surrounding 
gap of the implant (Figure 4). The 2 components of osseoin-
tegration of the implant were measured by histomorphometry 
using a stereological system—an Olympus microscope BX50 
and Visiopharm Integrator system (NewCast version 3.0.9.0; 
Visiopharm, Hoersholm, Denmark). Gap healing was defined 
as volume density fraction of new bone in the ROI. The 
volume density was measured by counting 276 (SD 52) grid 
points hitting new bone per specimen. A mean of 1,539 (SD 
68) points was counted for each specimen and determined as 
being either new bone, allograft, fibrous tissue, bone marrow 
tissue, or BGE.
Ongrowth onto the implant was defined as surface density 
area fraction of new bone in contact with the implant sur-
face. At interceptions between the surface of the implant and 
randomly orientated gridlines, the tissue in contact with the 
implant was determined and counted as being either new bone, 
allograft, fibrous tissue, bone marrow tissue, or BGE. For each 
implant, a mean of 756 (SD 54) line intercepts was counted in 
total and a mean of 107 (SD 54) intercepts was counted for 
new bone in contact with the implant per specimen.
Ongrowth onto the BGE was also estimated, which was 
defined as new bone in contact with the surface of BGE 
granules. At intercepts between the surface of granules and 
randomly orientated gridlines, the tissue in contact with the 
granule was determined and counted as being either new bone, 
allograft, fibrous tissue, or bone marrow tissue. A mean of 833 
(SD 121) line intercepts was counted per implant and a mean 
of 264 (SD 101) intercepts was counted for new bone in con-
tact with BGE.
All estimates were counted at 250× magnification in ran-
domly sampled fields of view in 100% of the ROIs.
A single observer performed the histomorphometrical anal-
ysis and was blinded to the treatment of the specimens. The 
intraobserver variation was determined as coefficient of varia-
tion (CV) on double measurements of one randomly selected 
implant from each treatment arm (Table 2).
Mechanical testing
Thawed specimens were tested to failure by axial push-out 
of the implant on an MTS Bionics Test Machine (Eden Prai-
rie, MN). The test was performed blind and all specimens 
were evaluated in one session. The specimens were placed 
on a metal support jig with a 7.4-mm diameter central open-
ing and under a 5.0-mm diameter cylindrical test probe. The 
implant was centralized over the opening, thereby assuring a 
distance of 0.7 mm between the implant and the support jig. 
The direction of loading was from the cortical surface inward. 
A preload of 0.5 N was applied to standardize contact condi-
tions before initiating loading. The displacement rate was 5 
mm/min with a 500-N load cell. Data points for every 10 µm 
of displacement were entered into an excel spreadsheet. The 
force-displacement curve and the mechanical parameters were 
calculated from the spreadsheet (Baas 2008).
The mean length of the specimens was 2.6 (SD 0.2) mm and 
the mean diameter was 5.8 (SD 0.1) mm. Individual specimen 
lengths were used to normalize push-out parameters. Ultimate 
shear strength (Pa) was determined from the maximal force 
applied until failure of the bone-implant interface (determined 
by a sudden drop in force applied to the implant). Apparent 
shear stiffness (Pa/mm) was obtained from the slope of the 
linear section of the load-deformation curve. Total energy 
absorption (in J/m2) was calculated from the area beneath 
the load-deformation curve until failure (Soballe 1993, Baas 
2008). 
1 pair of samples had to be excluded from the mechanical 
test because one of the implants had been misplaced during 
surgery, resulting in the superficial part (the part used for 
mechanical testing) not having bone coverage on a small part 
of the circumference.
Statistics
Statistical analysis was performed using Intercooled STATA 
10.0 software. In this paired study, the data of the differences 
between treatment arms were not normally distributed for all 
variables. The data were therefore transformed by natural loga-
rithm (ln) and found to be normally distributed on the ln scale. 
An absolute difference between the ln of a pair of data equals 
the ln of the ratio within the pair (Bland and Altman 1996). 
2-tailed p-values below 0.05 were considered statistically sig-
nificant. Results are presented as medians of relative differ-
ences between the paired data. The 95% confidence intervals 
(CIs) were obtained by back transformation of ln-transformed 
data unless otherwise stated. Calculations of CV% for each 
variable were done via calculations of transformed mean and 
transformed standard deviation (SD) (Aitchison 1957).
Figure 4. Manually drawn region of interest (ROI) 2.45 mm from the 
implant surface, shown by the complete circle. BGE, implant with 
porous coating of beads. The circle with the dashed line shows the 
approximate position of the drill hole. 1.25× objective.618  Acta Orthopaedica 2011; 82 (5): 614–621
Results
All the histological parameters with an intraobserver CV of 
less than 20% were statistically tested (Table 2).
In the gap, strontium-doped hydroxyapatite (SrHA) induced 
a statistically significant 21% (CI: 9–35) increase in new bone 
and 18% (CI: 2–37) more allograft was present compared 
to HA BGE (Figures 5 to 8). The volume of the BGE was 
the same for the two treatment arms regardless of strontium 
doping (–0.2% (CI: –14 to 11)). A statistically significantly 
greater fraction of the surface area of the SrHA BGE mate-
rial was also in contact with new bone compared to HA BGE 
(Figures 5 and 6 and Table 3).
On the surface of the implant, no statistically significant 
difference between treatment arms was found for the area 
fraction of new bone and fibrous tissue in contact with the 
implant surface. Differences were observed for both param-
eters in favor of improved osseointegration, but the differences 
could not be verified statistically at the 5% significance level 
chosen for this study (Table 3). The same overall results of 
statistically non-significant improvement were also found for 
the mechanical parameters ultimate shear strength and total 
energy absorption. The apparent shear stiffness was the same 
for the 2 treatment arms regardless of the strontium doping 
(Table 4).
 
Discussion
Strontium-doped hydroxyapatite (SrHA) as a bone graft 
extender (BGE) improved gap healing, preserved more of the 
impacted, morselized allograft, and increased ongrowth of 
Table 2. Intraobserver variation presented as coefficient of variation 
(%) for all parameters counted
  New bone  Allograft  Fibrous tissue  BGE
Gap healing  8.7  18  72    11
Ongrowth, implant  15  0.0  9  101
Ongrowth, BGE  3.7  0.0  53  NA
Figure 5. The implant-bone interface showing gap healing and 
ongrowth of bone onto the implant and SrHA. New bone (N), preserved 
allograft (A), ongrowth onto the implant (thin arrow), and ongrowth onto 
the SrHA (thick arrow). 10× objective.
Figure 6. The implant-bone interface showing gap healing and 
ongrowth of bone onto the implant and HA. New bone (N), preserved 
allograft (A), ongrowth onto the implant (thin arrow), and ongrowth onto 
the HA (thick arrow). 10× objective.
Table 3. Ongrowth of bone onto implant and BGE. Histomorphometrical results of surface 
area fractions of the implant and BGE presented as mean values in per cent with 95% CI 
in parentheses. The difference between the 2 treatment arms is presented as a median 
ratio (95% CI). Variation in the data is presented as CV%
  Treatment arms
  SrHA  HA  Ratio  CV% p-value
Implant
   New bone  15 (10–21)  13 (7.9–18)  1.25 (0.86–1.8)    56  0.2
   Allograft  0    0   NA  NA  NA
   Fibrous tissue  27 (9.1–45)  29 (11–46)  0.59 (0.18–1.9)  309  0.3 
BGE
   New bone  36 (30–41)  28 (18–37)  1.39 (1.1–1.8)    41  0.03
   Allograft  0   0   NA  NA  NAActa Orthopaedica 2011; 82 (5): 614–621  619
bone onto the BGE. This was statistically evident in the the 
present study of a Ti implant sorrounded by allograft mixed 
with hydroxyapatite (HA) as a BGE  with or without strontium 
doping. Type-1 error cannot be ruled out due to the multiple 
comparisons. We did not prove the main hypothesis that stron-
tium doping of the BGE improves histological and mechani-
cal implant fixation. The unexpectedly high CV of above 30% 
for the non-significant differences between the treatment arms 
may have prevented us from detecting a real difference induced 
by strontium doping of the BGE (type-2 error). Thus, the high 
CV of 56% for ongrowth of bone onto the implant might have 
caused the observed increase in bone ongrowth by strontium to 
be non-significant. The possibility of type-2 error is supported 
by the statistically significantly increased gap healing and non-
significant decrease in fibrous tissue in contact with the implant. 
Ultimate shear strength and total energy absorption were 
increased, but not statistically significantly so. While not all 
significant, all the variables indicated that there was improved 
histological and mechanical implant fixation. Overall, we inter-
pret these non-significant results as being inconclusive.
We assume that strontium was indeed released from the 
strontium hydroxyapatite (Christoffersen et al. 1997). Since all 
other variables were constant, strontium most likely induced 
the effects that were evident statistically in this study.
Strontium is believed to simulate a homeostatic local hyper-
calcemia. The reason is that strontium, as also for calcium, 
is believed to stimulate the calcium-sensing receptor CaSR 
Figure 8. Paired plot of preserved allograft. The difference in ratio was 
1.18 (1.02–1.4); p = 0.03. 
Figure 7. Paired plot of gap healing. The difference in ratio was 1.21   
(1.1–1.4); p = 0.003.
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Table 4. Results of the mechanical push-out test presented as mean values with 95% CI in parentheses. The 
difference between the two treatment arms is presented as median ratio with 95% CI in parentheses. Varia-
tion in the data is presented as CV%
  Treatment arms
  SrHA  HA  Ratio  CV% p-value
Ultimate shear strength, MPa  2.3 (1.3–3.2)  2.1 (0.76–3.5)  1.25 (0.74–2.1)  75  0.4
Apparent shear stiffness, MPa/mm  12 (7.1–17)  14 (5–23)  1 (0.57–1.7)  83  1
Total energy absorption, kJ/m2  415 (211–619)  310 (87–532)  1.62 (0.93–2.8)  82  0.08 
(Fromigue et al. 2009). The receptor is situated in the mem-
brane of cells of the osteoblast cell line and affects RANKL 
production and signaling to osteoclasts (Brennan et al. 2009). 
With regard to osteoclasts, strontium is known to reduce their 
proliferation and differentiation and it may even induce apop-
tosis of osteoclasts, which generally reduces resorption of 
bone (Buehler et al. 2001, Bonnelye et al. 2008). Strontium is 
also known to enhance the proliferation and differentiation of 
osteoblasts, which leads to a larger pool of active osteoblasts 
and thus to an increase in new bone formation (Canalis et al. 
1996, Arlot et al. 2007, Atkins et al. 2009).
In this study, these effects of SrHA had two important con-
sequences. Firstly, SrHA increased the healing of the gap sur-
rounding the implant, which was evident from the increased 
volume of new bone in the gap. Secondly, the resorption of 
the allograft was delayed when mixed with SrHA, which was 
evident from the increased volume of allograft in the gap after 
4 weeks.
We used dogs because their bone shows great resemblances 
to human bone. Bone turnover in dogs is higher than in 
humans, so perhaps a greater response to a stimulus such as 
strontium would be observed in dogs (Kimmel and Jee 1982, 
Shaw et al. 1994, Aerssens et al. 1998).
We chose BGE granules with a diameter of 0.6–2.0 mm 
because this is recommended for clinical settings (Hing 2005). 
Then, during the mechanical push-out test, we observed that 
the size of some of the bone graft extender granules was close 620  Acta Orthopaedica 2011; 82 (5): 614–621
to the full height of the specimen block. So depending on the 
position and orientation of large granules of up to 2 mm in 
diameter, situated in close proximity to the implant, this could 
either have weakened or strengthened the mechanical proper-
ties of the interface in this specific model. In contrast, in a typ-
ical clinical setting the height of the gap is greater than the 2.6 
mm of the specimen blocks that were subjected to mechanical 
testing of this study, so the relative size of granules would be 
smaller and of less importance for the mechanical properties 
of the interface. The issue of granule size may have contrib-
uted to the large variation in the data from the mechanical test-
ing. The exclusion of 1 sample pair weakened the power of the 
mechanical test, which may have exacerbated the influence of 
the large variation in data to exceed the expected CVdiff = 
30% that was entered in the initial calculation of sample size.
In summary, Ti-alloy implants can become osseointegrated 
when surrounded by this particular bone graft extender (BGE) 
of precipitated HA mixed with allograft. This allowed us to 
investigate whether doping of the bone graft extender with 5% 
strontium would have any effect on the osseointegration of the 
implant. The new finding of our study was that histologically, 
strontium doping of the BGE statistically significantly regu-
lated the imbalance of rapid allograft resorption and relatively 
slow formation of new bone in the gap. Thus, strontium doping 
of bone graft extender can be beneficial when an allograft is 
used during joint replacement surgery. The statistical power of 
our study was low due to the larger than expected variation in 
data and because of the loss of 1 sample pair in the mechanical 
testing. Further investigation is needed to confirm our findings 
and to determine whether strontium doping of the BGE can 
improve the full osseointegration and mechanical fixation of 
allografted implants.
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